Navigation Links
ConocoPhillips establishes $22.5M biofuels research program at Iowa State

ConocoPhillips will establish an eight-year, $22.5 million research program at Iowa State University dedicated to developing technologies that produce biorenewable fuels. The grant is part of ConocoPhillips' plan to create joint research programs with major universities to produce viable solutions to diversify America's energy sources.

ConocoPhillips will make an initial $1.5 million grant in 2007 to support Iowa State researchers, with additional grants of $3 million per year for seven years.

Biorenewable fuels are produced from organic materials and help reduce pollution and greenhouse gas emissions while diversifying the energy supply. Conventional biorenewable fuels include ethanol from corn starch and biodiesel from soybean oil. Advanced biofuels are expected to be made from fibrous biomass such as the stalks and leaves from corn plants and switchgrass.

"I'm pleased Iowa State University and ConocoPhillips will partner to research and develop new technologies for producing biofuels," said Iowa Gov. Chet Culver. "These kind of public-private partnerships are an important part of my plan to fuel Iowa's future. Private sector investments will be the driving force behind the development of new industries and technologies, and I'm encouraged that Iowa State and ConocoPhillips are working together to create the right research programs for our state's energy future."

"We believe the key to a secure energy future is the efficient and effective use of a diverse mix of energy sources," said Jim Mulva, chairman and chief executive officer of ConocoPhillips. "ConocoPhillips is developing long-term relationships with respected academic institutions such as Iowa State to research extensions of traditional energy sources that ultimately will benefit consumers."

"We are excited to work with ConocoPhillips to develop a research program that applies Iowa State University's strengths in renewable energy," said Iowa State President
'"/>

Source:Iowa State University


Page: 1 2 3

Related biology news :

1. New molecule may aid in production of biofuels and fungi-resistant plants
2. New biofuels process promises to meet all US transportation needs
3. Columbia research lifts major hurdle to gene therapy for cancer
4. U of M researcher examines newly emerging deadly disease
5. NYU researchers simulate molecular biological clock
6. First atlas of key brain genes could speed research on cancer, neurological diseases
7. New research questions basic tenet of neuron function
8. Vital step in cellular migration described by UCSD medical researchers
9. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
10. UCSD researchers maintain stem cells without contaminated animal feeder layers
11. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers

Post Your Comments:
(Date:11/23/2009)...ciated strain of the deadly superbug MRSAan infect...bioticsposes a far greater health threat than prev... according to a study in the December issue of Em...s easily picked up in fitness centers, schools, an...l burden of MRSA within hospitals, the report foun...
(Date:11/23/2009)...gests that a common oral bacterium may exacerbate ... et al, "Unique Lipids from a Common Human Bacteri...f Enhancing Autoimmunity," appears in the December.... , Multiple sclerosis (MS), a disease where the...affects nearly 1 in 700 people in the United State...
(Date:11/23/2009)... University of Alabama at Birmingham (UAB) researc...ing medical conditions (co-morbidity) do not expla...mericans compared to Caucasians who also have colo... Cancer , a journal of the American Cancer Societ... co-morbidity are independent predictors of poor s...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 1VIASPACE Pursuing Renewable Energy Business in Asia 13353 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 1Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 2Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 4Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 5Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 6Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 1Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 2Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 3Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 4Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 5Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 6Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 7Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 8Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 9Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 10Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 11Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 12Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 13Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 14Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 15Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 16Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 17Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 18Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 19Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 20Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 21Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 22Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 23
...veling the complex mechanisms in the brain that re...etites are controlled by systems very similar to t...type of neuron that is essential for feeding behav... and undergo rapid weight loss. , Remarkably, th...only influenced eating behavior when they were rem...
...des insight into genetic basis of human diseaseHig...lds a map of genetic variation which can give clue...he current technologies collect genotypes, or info...t many scientists believe that drilling down to th... of each chromosome -- so-called haplotypes -- wil...
...he last ice age are the likely culprits in the ext...rican great mammals such as mammoths, mastodons an...da researcher. , Determining whether the first arr...inent at the end of the last Ice Age was responsib...d scientists because both events occurred at the s...
Other Biology News:An essential regulator of body weight revealed 2An essential regulator of body weight revealed 3An essential regulator of body weight revealed 4California computer scientists double volume of data in NIH biotech repository 2California computer scientists double volume of data in NIH biotech repository 3California computer scientists double volume of data in NIH biotech repository 4Study shows big game hunters, not climate change, killed off sloths 2Study shows big game hunters, not climate change, killed off sloths 3
(Date:11/24/2009)... Health care employment grew ...he only one to show consistent growth during the U...itals remain in trouble, and health systems are co...onnel, instead of just administrators. , ...h care employment continued growing in October des...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--NODPharmaceuti...PTO)hasallowedthepatentapplicationfor,itsnano-part...ogyisahighlyefficientapproachtoincorporatepeptides...raldeliveryofdrugs,otherwiseadministeredasinjectio...liedtomanymacromoleculardrugssuchasinsulin,interfe...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiolax...ion(SFDA)hasapprovedthe,investigationalnewdrugappl...novativeinsulinformulationtotreatdiabetes.ThisIND,...calstudy. , Diabetesisadisordercharacteristic...onsofdiabetesoftenresultinseveremicro-and,macro-va...
(Date:11/24/2009)... The FBI recently approved the ...ries participating in or generating DNA records fo... Madison, WI USA (PRWEB) -- The FBI recen...tem for use by laboratories participating in, or ... System (NDIS). NDIS currently contains more than ...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2
...ONDON, Aug. 27 Following the successful acquisiti...ry, Chiltern, a leading,contract research organiza... its two early Phase units into a single operation... Phase is providing high quality early phase servi...ll established units in Slough,(just outside of Lo...
...AN DIEGO and INDIANAPOLIS, Aug. 26 Amylin,Pharmac...Company (NYSE: LLY ),in a conference call today p...ng the August 18, 2008 U.S. Food and Drug Administ... (exenatide) injection referencing,pancreatitis. T...referenced,in the alert, as well as others, and pr...
...otes Secured by Royalties on U.S. Sales of SANCTUR...26 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV )...ement to institutional investors of $105.0 million...e secured by royalties to be,paid from sales in th...,(trospium chloride). SANCTURA and SANCTURA XR are...
Other Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 2Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 3Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 4
Rabbit Anti-Schizosaccharomyces pombe SpUlp2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Human STX18 Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-Human sRANKL Polyclonal Antibody, Biotin Conjugated from Cell Sciences
Mouse Anti-CD42d Monoclonal Antibody, Unconjugated, Clone CLB-SW16 (formerly 708) from Abcam
Biology Products: